Global Oral Medications for Parkinson's Disease Market Growth 2024-2030

Global Oral Medications for Parkinson's Disease Market Growth 2024-2030

Oral medications are a cornerstone of treatment for Parkinson's disease, a neurodegenerative disorder characterized by motor symptoms such as tremors, stiffness, and impaired movement. These medications are primarily designed to manage symptoms and improve quality of life by addressing the underlying dopamine deficiency in the brain. The most commonly prescribed drug is Levodopa, often combined with Carbidopa, which helps convert Levodopa into dopamine while minimizing side effects. Other oral medications include dopamine agonists that mimic dopamine's effects, MAO-B inhibitors that prevent the breakdown of brain dopamine, COMT inhibitors that prolong Levodopa's effects, and anticholinergics that help control tremors. Amantadine, an antiviral, is also used to manage symptoms and dyskinesia.

The global Oral Medications for Parkinson's Disease market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.

LP Information, Inc. (LPI) ' newest research report, the “Oral Medications for Parkinson's Disease Industry Forecast” looks at past sales and reviews total world Oral Medications for Parkinson's Disease sales in 2023, providing a comprehensive analysis by region and market sector of projected Oral Medications for Parkinson's Disease sales for 2024 through 2030. With Oral Medications for Parkinson's Disease sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Oral Medications for Parkinson's Disease industry.

This Insight Report provides a comprehensive analysis of the global Oral Medications for Parkinson's Disease landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Oral Medications for Parkinson's Disease portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Oral Medications for Parkinson's Disease market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Oral Medications for Parkinson's Disease and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Oral Medications for Parkinson's Disease.

United States market for Oral Medications for Parkinson's Disease is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Oral Medications for Parkinson's Disease is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Oral Medications for Parkinson's Disease is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Oral Medications for Parkinson's Disease players cover AbbVie, Merck, Boehringer Ingelheim, GlaxoSmithKline, Novartis Pharma, etc. In terms of revenue, the global two largest companies occupied for a share nearly

% in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Oral Medications for Parkinson's Disease market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
L-Dopa Formulations
Dopamine Agonists
Mao-B Inhibitors
COMT Inhibitors

Segmentation by Application:
Under 40 Years Old
40-65 Years Old
Above 65 Years Old

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
AbbVie
Merck
Boehringer Ingelheim
GlaxoSmithKline
Novartis Pharma
Supernus Pharmaceuticals
Bausch Health
Newron Pharmaceuticals
Teva Pharmaceutica
Glenmark Pharmaceuticals
Orion Pharma
Neurocrine Biosciences
Kyowa Kirin
UCB
Desitin Arzneimittel
Amneal Pharmaceuticals
Organon Pharma
F.Hoffmann-La Roche
Lundbeck
Stada

Key Questions Addressed in this Report

What is the 10-year outlook for the global Oral Medications for Parkinson's Disease market?

What factors are driving Oral Medications for Parkinson's Disease market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Oral Medications for Parkinson's Disease market opportunities vary by end market size?

How does Oral Medications for Parkinson's Disease break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.